Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Editorial: Coronavirus Disease (COVID-19): Pathophysiology, Epidemiology, Clinical Management and Public Health Response, Volume II.

Autor: Barin B; The Emmes Company, LLC, Rockville, MD, United States., Kozlakidis Z; International Agency for Research on Cancer, World Health Organization, Lyon, France., Ricci F; Department of Neuroscience, Imaging and Clinical Sciences, G.d'Annunzio University of Chieti-Pescara, Chieti, Italy., Su L; Department of Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China., Tsioutis C; School of Medicine, European University Cyprus, Nicosia, Cyprus., Welburn SC; Infection Medicine, Deanery of Biomedical Sciences, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, United Kingdom.; Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Haining, China., Ropert C; Department of Biochemistry and Immunology, Institute of Biological Sciences (ICB), Federal University of Minas Gerais, Belo Horizonte, Brazil., Iosa M; Department of Psychology, Sapienza University of Rome, Rome, Italy.; Smart Lab, IRCCS Fondazione Santa Lucia, Rome, Italy., Rawson T; Medical Research Council (MRC) Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, United Kingdom., Sun J; Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China., Lumbers ER; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW, Australia.; Pregnancy and Reproduction Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.; Priority Research Centre for Reproductive Sciences, University of Newcastle, Newcastle, NSW, Australia.

Publikováno v: Frontiers in public health [Front Public Health] 2022 Jun 07; Vol. 10, pp. 913507. Date of Electronic Publication: 2022 Jun 07 (Print Publication: 2022).

Impact of IFN-γ Deficiency on the Cardiomyocyte Function in the First Stage of Experimental Chagas Disease.

Autor: Roman-Campos D; Laboratório de Cardiobiologia, Department of Biophysics, Federal University of São Paulo, São Paulo 04021, Brazil., Sales-Junior P; Oswaldo Cruz Foundation, Eusébio 61760, Brazil., Costa AD; Laboratório de Membranas Excitáveis e de Biologia Cardíaca, Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte 31270, Brazil., Souza DS; Laboratório de Cardiobiologia, Department of Biophysics, Federal University of São Paulo, São Paulo 04021, Brazil., Santos-Miranda A; Laboratório de Cardiobiologia, Department of Biophysics, Federal University of São Paulo, São Paulo 04021, Brazil., Joviano-Santos JV; Laboratório de Cardiobiologia, Department of Biophysics, Federal University of São Paulo, São Paulo 04021, Brazil., Ropert C; Laboratório de Membranas Excitáveis e de Biologia Cardíaca, Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte 31270, Brazil., Cruz JS; Laboratório de Membranas Excitáveis e de Biologia Cardíaca, Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte 31270, Brazil.

Publikováno v: Microorganisms [Microorganisms] 2022 Jan 25; Vol. 10 (2). Date of Electronic Publication: 2022 Jan 25.

Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database.

Autor: Alexandre J; PICARO Cardio-oncology Program, Department of Pharmacology, Normandie University, UNICAEN, CHU de Caen Normandie, EA 4650, Signalisation, électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique, F-14000 Caen, France., Salem JE; Department of Pharmacology, AP-HP, Pitié-Salpêtrière Hospital, CIC-1421, INSERM, UMR ICAN 1166, Sorbonne Université, APHP.6 Cardio-oncology Program, F-75013 Paris, France.; Department of Medicine, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN 37240, USA., Moslehi J; Department of Medicine, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN 37240, USA., Sassier M; Department of Pharmacology, CHU de Caen Normandie, PICARO Cardio-oncology Program, F-14000 Caen, France., Ropert C; Department of Cardiology, CHU de Caen Normandie, F-14000 Caen, France., Cautela J; Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Mediterranean University Cardio-Oncology Center, Hôpital Nord, Marseille 13915, France.; Centre de Recherche Cardiovasculaire et Nutrition, Inserm 1263, Inra, Marseille 13915, France.; Groupe Méditerranéen de Cardio-Oncologie, Marseille 13915, France.; Oncosafety Network of the Early Phases Cancer Trials Center, Marseille 13915, France., Thuny F; Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Mediterranean University Cardio-Oncology Center, Hôpital Nord, Marseille 13915, France.; Centre de Recherche Cardiovasculaire et Nutrition, Inserm 1263, Inra, Marseille 13915, France.; Groupe Méditerranéen de Cardio-Oncologie, Marseille 13915, France.; Oncosafety Network of the Early Phases Cancer Trials Center, Marseille 13915, France., Ederhy S; Hôpitaux Universitaires Paris-Est, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, Service de cardiologie, Unico, Unité de cardio-oncologie APHP.6, GRC Groupe de recherche clinique en cardio oncologie, Inserm 856, Université Pierre et Marie Curie, Paris, France., Cohen A; Hôpitaux Universitaires Paris-Est, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, Service de cardiologie, Unico, Unité de cardio-oncologie APHP.6, GRC Groupe de recherche clinique en cardio oncologie, Inserm 856, Université Pierre et Marie Curie, Paris, France., Damaj G; Department of Hematology, CHU de Caen Normandie, F-14000 Caen, France., Vilque JP; Department of Hematology, CHU de Caen Normandie, F-14000 Caen, France., Plane AF; Department of Cardiology, CHU de Caen Normandie, F-14000 Caen, France., Legallois D; Department of Cardiology, Normandie University, UNICAEN, CHU de Caen Normandie, EA 4650, Signalisation, électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique, F-14000 Caen, France., Champ-Rigot L; Department of Cardiology, Normandie University, UNICAEN, CHU de Caen Normandie, EA 4650, Signalisation, électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique, F-14000 Caen, France., Milliez P; Department of Cardiology, Normandie University, UNICAEN, CHU de Caen Normandie, EA 4650, Signalisation, électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique, F-14000 Caen, France., Funck-Brentano C; Department of Medicine, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN 37240, USA., Dolladille C; PICARO Cardio-oncology Program, Department of Pharmacology, Normandie University, UNICAEN, CHU de Caen Normandie, EA 4650, Signalisation, électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique, F-14000 Caen, France.

Publikováno v: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2021 Jul 23; Vol. 7 (4), pp. 312-320.